Ruixin Medical and Philips Announce Strategic Collaboration to Advance Integrated AI-Driven Interventional Solutions

Jun 02, 2026 12:28 CST Updated 12:28

RaysightMed

Medical Imaging Product Developer

Recently,RaysightMed and Philips Imaging Officially Sign Strategic Cooperation Agreement. Leveraging their respective core technologies and industrial resource endowments, both parties are delving deep into the potential for collaborative innovation, utilizing artificial intelligence to break through bottlenecks in the development of interventional diagnosis and treatment. This strategic synergy enables complementary advantages between interventional platforms and intelligent diagnostic technologies, propelling interventional medicine into a new phase of high-quality, value-driven development.

As a leading enterprise in AI-based diagnosis of cardiovascular function, RaysightMed has always remained committed to its original mission of “safeguarding longer-lasting life rhythms with intelligent technology,” deeply cultivating the field of precise diagnosis and treatment of cardiovascular diseases. This partnerPhilips is a global leader in health technology. Since its launch in 2017, the Azurion platform, the core of its image-guided therapy solutions, has been deployed in more than 80 countries and regions worldwide, serving over 6.4 million patients annually, with its clinical safety and practicality extensively validated.Leveraging its global technological expertise and localized clinical insights in China, Philips is collaborating with local partners to build a comprehensive ecosystem for interventional diagnosis and treatment, driving the industry’s transformation from technology-driven to value-oriented.

Looking ahead, RaysightMed will leverage core technologies such as AI deep learning, 3D computational fluid dynamics (CFD) simulation, and intelligent robotics. From the globally leading non-invasive Ruixin FFR and comprehensive coronary functional assessment system, to the fully automated AI-guided vascular interventional surgical robot, and further to its intelligent evaluation framework, the company has established a full-chain intelligent diagnosis and treatment closed loop that spans screening and diagnosis, interventional therapy, and post-operative follow-up management. RaysightMed remains committed to its mission of becoming the leader in integrated smart solutions for precise cardiac diagnosis and treatment.